Arrowhead Pharmaceuticals, Inc. (ARWR)
| Previous Close | 24.13 |
| Open | 25.05 |
| Bid | 24.20 x 200 |
| Ask | 24.42 x 100 |
| Day's Range | 24.14 - 25.24 |
| 52 Week Range | 20.67 - 42.48 |
| Volume | |
| Avg. Volume | 1,279,791 |
| Market Cap | 3.018B |
| Beta (5Y Monthly) | 0.72 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Business Wire
Arrowhead Pharmaceuticals Earns $50 Million Milestone from Royalty Pharma
PASADENA, Calif., May 02, 2024--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced a $50 million milestone payment was received from Royalty Pharma plc (NASDAQ: RPRX). This milestone was triggered after the completion of enrollment of the Phase 3 OCEAN(a) - Outcomes Trial of olpasiran, being conducted by Amgen (NASDAQ: AMGN). Pursuant to its 2016 agreement with Amgen and 2022 agreement with Royalty Pharma, Arrowhead is further eligible to receive up to an additional $375 million from
- Business Wire
Arrowhead Pharmaceuticals to Participate in Upcoming May 2024 Conferences
PASADENA, Calif., April 29, 2024--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events:
- Business Wire
Arrowhead Pharmaceuticals to Host 2024 Summer Series of R&D Webinars
PASADENA, Calif., April 26, 2024--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced its plan to host a 2024 Summer Series of R&D webinars that highlight multiple clinical stage RNA interference (RNAi) based medicines that utilize the company’s proprietary Targeted RNAi Molecule (TRiMTM) platform. Each webinar in the Summer Series will focus on a specific therapeutic area and will feature presentations by Arrowhead team members about the company’s clinical candidates and external key
